Improving adherence to psoriasis treatment with deucravacitinib

Deucravacitinib Adherence Study

This study is testing whether sending text reminders can help people with moderate-to-severe psoriasis stick to their oral treatment with deucravacitinib and how that affects their health outcomes.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Wake Forest University Health Sciences (other)
• Drugs / interventions: deucravacitinib
• Locations: 1 site (Winston-Salem, North Carolina)
• Trial ID: NCT05570955 on ClinicalTrials.gov

What this trial studies

This study focuses on enhancing adherence to the oral treatment of psoriasis using deucravacitinib. Forty patients with moderate-to-severe plaque psoriasis will be recruited from Wake Forest Baptist Health Dermatology Clinic, with half receiving a text reminder intervention aimed at improving adherence. The study will also involve qualitative interviews to explore the beliefs and behaviors of patients with varying levels of adherence. Additionally, treatment outcomes and efficacy will be compared between highly adherent and less adherent patients.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with moderate-to-severe plaque psoriasis.

Not a fit: Patients with mild psoriasis or those with severe comorbid conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment outcomes for psoriasis patients by enhancing their adherence to medication.

How similar studies have performed: Other studies have shown that interventions to improve medication adherence can lead to better health outcomes, suggesting potential success for this approach.

Eligibility criteria

Inclusion Criteria:

* Patients with moderate-to-severe plaque psoriasis. Standard criteria for moderate-to-severe plaque psoriasis will be used (BSA greater than or equal to 3% or face/palm/sole/genital involvement or severe effect on Quality of Life).
* Subject must be 18 years of age or older.
* Subject must have a working knowledge of English.
* Approved birth control methods required for females of childbearing potential.
* Baseline TB test.

Exclusion Criteria:

* Patients without a diagnosis of moderate-to-severe plaque psoriasis.
* Patients under 18 years of age.
* Patients with severe or unstable comorbid conditions.
* Patients with active malignancy or malignancy in past 5 years (not including appropriately treated cutaneous basal and cutaneous-limited squamous cell carcinomas).
* Patients who are pregnant or breastfeeding.
* Patients with any other skin condition that prohibit or confound the ability of the investigator to interpret skin findings.
* Patients with active substance or alcohol abuse disorder; or history of substance/alcohol abuse disorder within 6 months prior to study enrollment.
* History of, or active, severe depression and/or suicidality.
* Patients with active or latent tuberculosis as determined by quant-TB baseline testing
* Patients that are taking concomitant biologics, systemics for the treatment of psoriasis and/or phototherapy.

Where this trial is running

Winston-Salem, North Carolina

• Wake Forest University Health Sciences Department of Dermatology — Winston-Salem, North Carolina, United States (RECRUITING)

Study contacts

• Principal investigator: Steven R Feldman, MD, PhD — Wake Forest University Health Sciences
• Study coordinator: Irma M Richardson, MHA

Conditions: Psoriasis